Helmholtz Gemeinschaft


High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds

Item Type:Article
Title:High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds
Creators Name:Zampieri, M. and Szappanos, B. and Buchieri, M.V. and Trauner, A. and Piazza, I. and Picotti, P. and Gagneux, S. and Borrell, S. and Gicquel, B. and Lelievre, J. and Papp, B. and Sauer, U.
Abstract:Rapidly spreading antibiotic resistance and the low discovery rate of new antimicrobial compounds demand more effective strategies for early drug discovery. One bottleneck in the drug discovery pipeline is the identification of the modes of action (MoAs) of new compounds. We have developed a rapid systematic metabolome profiling strategy to classify the MoAs of bioactive compounds. The method predicted MoA-specific metabolic responses in the nonpathogenic bacterium Mycobacterium smegmatis after treatment with 62 reference compounds with known MoAs and different metabolic and nonmetabolic targets. We then analyzed a library of 212 new antimycobacterial compounds with unknown MoAs from a drug discovery effort by the pharmaceutical company GlaxoSmithKline (GSK). More than 70% of these new compounds induced metabolic responses in M. smegmatis indicative of known MoAs, seven of which were experimentally validated. Only 8% (16) of the compounds appeared to target unconventional cellular processes, illustrating the difficulty in discovering new antibiotics with different MoAs among compounds used as monotherapies. For six of the GSK compounds with potentially new MoAs, the metabolome profiles suggested their ability to interfere with trehalose and lipid metabolism. This was supported by whole-genome sequencing of spontaneous drug-resistant mutants of the pathogen Mycobacterium tuberculosis and in vitro compound-proteome interaction analysis for one of these compounds. Our compendium of drug-metabolome profiles can be used to rapidly query the MoAs of uncharacterized antimicrobial compounds and should be a useful resource for the drug discovery community.
Keywords:Anti-Infective Agents, Mass Spectrometry, Metabolomics, Microbial Sensitivity Tests, Mycobacterium smegmatis
Source:Science Translational Medicine
Publisher:American Association for the Advancement of Science
Page Range:eaal3973
Date:21 February 2018
Official Publication:https://doi.org/10.1126/scitranslmed.aal3973
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library